MENLO PARK, Calif. & PADOVA, Italy--(BUSINESS WIRE)--March 29, 2006--Depomed, Inc. (Nasdaq:DEPO) and Madaus S.r.l. today announced that the Marketing Authorization Application (MAA) for ProQuin(R) XR was accepted for review by the Medical Products Agency in Sweden. Madaus submitted the MAA earlier this year, seeking approval for ProQuin XR for the treatment of uncomplicated urinary tract infections. ProQuin XR is a once-daily, prolonged release formulation of ciprofloxacin hydrochloride, which was developed by Depomed.
